From DND's perspective, yes, we do need the analyses. It is a recommendation and it is based on a pharmaco-economic analysis that takes an uptake of the drug in each jurisdiction. Because we have various jurisdictions with quite a varying population, that uptake may not be the same as what CDR has looked at.
We're not a province. We don't have the population of a province, so it may not impact us financially as much as it would one of the provinces; therefore, given our individual mandates, we have to determine whether we can afford it within our resources.